Skip to main content
OpenTrials
Recruiting

NCT Number: NCT03378739

Inova Cardiogenic Shock Registry (INOVA SHOCK)

To collect retrospective clinical outcomes related to acute decompensated heart failure cardiogenic shock, acute myocardial infarction cardiogenic shock and compare current versus historical survival rates.

To collect Inova Heart and Vascular Institute (IHVI) site specific outcomes before and after initiation of the Cardiogenic Shock team on January 1, 2017.

To collect outcomes related to implementation of mechanical circulatory support versus no circulatory intervention and type of intervention (extracorporeal membrane oxygenation (ECMO) versus intracorporeal axial-flow (Impella).

• Assess survival at three time points.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Cardiogenic Shock Cardiovascular Diseases Heart Diseases Infarction Ischemia Myocardial Infarction Myocardial Ischemia Necrosis Pathologic Processes Pathological Conditions, Signs and Symptoms Shock Shock, Cardiogenic Vascular Diseases

Age range

18 year–85 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Inova Fairfax Hospital

Falls Church, Virginia, 22042, United States

Location status: Recruiting

Location contact

Alex Truesdell, MD

PRINCIPAL_INVESTIGATOR

Behnam Tehrani, MD

CONTACT

Benham Tehrani, MD

SUB_INVESTIGATOR

About this study

Any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the Inova Heart and Vascular Institute shall be included in this registry. This includes adults with and without decision making capacity over the age of 18 years old.

The primary investigator (PI) will designate the data points to be included in the database in order to assess the efficiency of procedures and protocols in the treatment of cardiogenic shock at the IHVI as administered by the Shock team, to identify relationships between treatment and negative morbidity and mortality outcomes, and to monitor and improve quality of care delivered.

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

-Patients at the IHVI with documented Cardiogenic Shock team intervention for acute decompensated heart failure cardiogenic shock, or acute myocardial infarction cardiogenic shock.

Exclusion criteria

-Patients under the age of 18 will be excluded.

Treatment and study plan

Cardiogenic Shock team activation

Procedure

Any patient with cardiogenic shock, whether inpatient or transferred from another facility, treated at the Inova Heart and Vascular Institute by the designated Cardiogenic Shock Team.

Primary outcomes

  1. Retrospective review of Cardiogenic shock patients outcomes

    Time frame: 1 Year

    To create an archive of retrospective clinical outcomes (acute decompensated heart failure cardiogenic shock, or acute myocardial infarction cardiogenic shock) and compare current versus historical survival rates.

Study contacts

Contact information is provided by the study sponsor or research team.

Bhruga Shah

CONTACT

[email protected]

703-776-2828

Sponsors and collaborators

Lead sponsor

Inova Health Care Services

Other

Registry information

Official study title

Implementation of a Cardiogenic Shock Team and Clinical Outcomes (INOVA-SHOCK Registry)

Acronym: INOVASHOCK

Important dates

Study start
2018
Primary completion
2099
Study completion
2099
First posted
Dec 20, 2017
Registry last updated
Mar 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.